CAR-T Cell Therapy Market Is Expected To Reach $10.5 Billion By 2031

MILWAUKEE - Nov. 1, 2021 - PRLog -- According to a new market research report published by sheer analytics and insights, "The Global CAR-T Cell Therapy Market was valued at $0.234 Billion in 2020. Growing at a high CAGR of more than 39.4% between 2021 and 2031, it is estimated to reach $10.5 Billion by 2031, as per the latest market research report titled CAR-T Cell Therapy Market- Industry analysis, size, share, growth, trends, and forecast, 2021-2031.

For many years, the foundations for cancer treatment have been chemotherapy, radiation therapy, and surgery. Over the past several years immunotherapy has emerged that enlist and strengthen the power of the patient's immune system so that they can attack tumors. It is now also known as the "fifth pillar" of cancer treatment. However, recently researchers have come up with more advanced treatments for cancer, known as, CAR-T Cell therapy.

What is this CAR-T Cell therapy?

CAR-T Cell therapy is a variation of immunotherapy popularly known as adoptive cell therapy. The T cells are the type of white blood cell that is extracted by the doctor from the patient's blood and then they add an artificial receptor to their surface. The receptor acts as a type of "heat-seeking missile" and this enables the modified cells to produce a type of chemicals that can kill cancer. Once they are infused back into the patient's body through an IV, they start multiplying and attack tumor cells.

The CAR-T cell is a type of antibody that induces modular-fusion protein having an extracellular specific binding domain. This therapy has made it possible to provide treatment against recurrence options for blood cancer and other carcinogenic cases. Needless to say, today CAR-T cell in the carcinogenic therapeutics field has become a boon to the healthcare industry. Owing to this factor many companies have started investing in CAR-T cell therapy which has increased its market and continues to do so. Presently, the most successful is the CD 19 antigen which is used for treating acute lymphoblastic leukemia (ALL). The Food and Drug Administration (FDA) has also approved the first genetic engineering which is based on Kymriah (tisagenlecleucel) by Novartis AG.

Click the full report at CAR-T Cell Therapy Market: https://www.sheeranalyticsandinsights.com/market-report-research/car-t-cell-therapy-market-21

The major companies operating in the global CAR-T cell therapy market are Novartis International AG, Kite Pharma Inc., Juno Therapeutics, Cellectis, Bellicum Pharmaceuticals Inc. and Celgene Corporation among others.